** InhaleRx IRX.AX rises 2.6% to A$0.04, highest since June 27
** Medical devices maker starts manufacturing its lead investigational product, IRX-211, for phase 2 of breakthrough cancer pain clinical trial
** About 537,948 shares traded, 1.6x the 30-day avg
** IRX gains 14.3% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.